Yurgelun, Matthew B.
Chittenden, Anu B.
Morales-Oyarvide, Vicente
Rubinson, Douglas A.
Dunne, Richard F.
Kozak, Margaret M.
Qian, Zhi Rong
Welch, Marisa W.
Brais, Lauren K.
Da Silva, Annacarolina
Bui, Justin L.
Yuan, Chen
Li, Tingting
Li, Wanwan
Masuda, Atsuhiro
Gu, Mancang
Bullock, Andrea J.
Chang, Daniel T.
Clancy, Thomas E.
Linehan, David C.
Findeis-Hosey, Jennifer J.
Doyle, Leona A.
Thorner, Aaron R.
Ducar, Matthew D.
Wollison, Bruce M.
Khalaf, Natalia
Perez, Kimberly
Syngal, Sapna
Aguirre, Andrew J.
Hahn, William C.
Meyerson, Matthew L.
Fuchs, Charles S.
Ogino, Shuji
Hornick, Jason L.
Hezel, Aram F.
Koong, Albert C.
Nowak, Jonathan A.
Wolpin, Brian M.
Article History
Received: 4 October 2017
Accepted: 20 March 2018
First Online: 2 July 2018
Disclosure
: Dr. Yurgelun has received prior research funding from Myriad Genetic Laboratories, Inc. Dr. Syngal has served as a consultant for Myriad Genetic Laboratories, Inc. Dr. Fuchs has served as a consultant for Lilly, Sanofi, Mayer, Merck, Entrinsic Health, Five Prime,Therapeutics, Agios, Gilead Sciences, Dicerna, Merrimack, Taiho Pharmaceutical, KEW Group, and Genentech/Roche. The remaining authors declare no conflicts of interest.